Report Thumbnail
Product Code LP091471047Z9W
Published Date 2023/2/22
English112 PagesGlobal

Global Telmisartan API Market Growth 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP091471047Z9W◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/22
English 112 PagesGlobal

Global Telmisartan API Market Growth 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

LPI (LP Information)' newest research report, the “Telmisartan API Industry Forecast” looks at past sales and reviews total world Telmisartan API sales in 2022, providing a comprehensive analysis by region and market sector of projected Telmisartan API sales for 2023 through 2029. With Telmisartan API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Telmisartan API industry.
This Insight Report provides a comprehensive analysis of the global Telmisartan API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Telmisartan API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Telmisartan API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Telmisartan API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Telmisartan API.
The global Telmisartan API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Telmisartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Telmisartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Telmisartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Telmisartan API players cover Jiangsu Zhongbang Pharmaceutical, Jiangxi Synergy Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zhejiang Tianyu Pharmaceutical, Zhuhai Rundu Pharmaceutical, Gonane Pharma, Dr. Reddy's Laboratories, Octavius Pharma Pvt. Ltd and Kekule Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Telmisartan API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
0.98
0.99
Others
Segmentation by application
Tablets
Capsules
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Jiangsu Zhongbang Pharmaceutical
Jiangxi Synergy Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Tianyu Pharmaceutical
Zhuhai Rundu Pharmaceutical
Gonane Pharma
Dr. Reddy's Laboratories
Octavius Pharma Pvt. Ltd
Kekule Pharma
Zeon Health Industries
Teva API
AGC Chemicals Europe
Actavis Inc.
Tokuyama Corporation
Hoventa Pharma
Saintsun Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Telmisartan API market?
What factors are driving Telmisartan API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Telmisartan API market opportunities vary by end market size?
How does Telmisartan API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Telmisartan API Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Telmisartan API by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Telmisartan API by Country/Region, 2018, 2022 & 2029
    • 2.2 Telmisartan API Segment by Type
      • 2.2.1 0.98
      • 2.2.2 0.99
      • 2.2.3 Others
    • 2.3 Telmisartan API Sales by Type
      • 2.3.1 Global Telmisartan API Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Telmisartan API Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Telmisartan API Sale Price by Type (2018-2023)
    • 2.4 Telmisartan API Segment by Application
      • 2.4.1 Tablets
      • 2.4.2 Capsules
      • 2.4.3 Others
    • 2.5 Telmisartan API Sales by Application
      • 2.5.1 Global Telmisartan API Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Telmisartan API Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Telmisartan API Sale Price by Application (2018-2023)
  • 3 Global Telmisartan API by Company

    • 3.1 Global Telmisartan API Breakdown Data by Company
      • 3.1.1 Global Telmisartan API Annual Sales by Company (2018-2023)
      • 3.1.2 Global Telmisartan API Sales Market Share by Company (2018-2023)
    • 3.2 Global Telmisartan API Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Telmisartan API Revenue by Company (2018-2023)
      • 3.2.2 Global Telmisartan API Revenue Market Share by Company (2018-2023)
    • 3.3 Global Telmisartan API Sale Price by Company
    • 3.4 Key Manufacturers Telmisartan API Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Telmisartan API Product Location Distribution
      • 3.4.2 Players Telmisartan API Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Telmisartan API by Geographic Region

    • 4.1 World Historic Telmisartan API Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Telmisartan API Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Telmisartan API Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Telmisartan API Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Telmisartan API Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Telmisartan API Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Telmisartan API Sales Growth
    • 4.4 APAC Telmisartan API Sales Growth
    • 4.5 Europe Telmisartan API Sales Growth
    • 4.6 Middle East & Africa Telmisartan API Sales Growth
  • 5 Americas

    • 5.1 Americas Telmisartan API Sales by Country
      • 5.1.1 Americas Telmisartan API Sales by Country (2018-2023)
      • 5.1.2 Americas Telmisartan API Revenue by Country (2018-2023)
    • 5.2 Americas Telmisartan API Sales by Type
    • 5.3 Americas Telmisartan API Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Telmisartan API Sales by Region
      • 6.1.1 APAC Telmisartan API Sales by Region (2018-2023)
      • 6.1.2 APAC Telmisartan API Revenue by Region (2018-2023)
    • 6.2 APAC Telmisartan API Sales by Type
    • 6.3 APAC Telmisartan API Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Telmisartan API by Country
      • 7.1.1 Europe Telmisartan API Sales by Country (2018-2023)
      • 7.1.2 Europe Telmisartan API Revenue by Country (2018-2023)
    • 7.2 Europe Telmisartan API Sales by Type
    • 7.3 Europe Telmisartan API Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Telmisartan API by Country
      • 8.1.1 Middle East & Africa Telmisartan API Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Telmisartan API Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Telmisartan API Sales by Type
    • 8.3 Middle East & Africa Telmisartan API Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Telmisartan API
    • 10.3 Manufacturing Process Analysis of Telmisartan API
    • 10.4 Industry Chain Structure of Telmisartan API
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Telmisartan API Distributors
    • 11.3 Telmisartan API Customer
  • 12 World Forecast Review for Telmisartan API by Geographic Region

    • 12.1 Global Telmisartan API Market Size Forecast by Region
      • 12.1.1 Global Telmisartan API Forecast by Region (2024-2029)
      • 12.1.2 Global Telmisartan API Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Telmisartan API Forecast by Type
    • 12.7 Global Telmisartan API Forecast by Application
  • 13 Key Players Analysis

    • 13.1 Jiangsu Zhongbang Pharmaceutical
      • 13.1.1 Jiangsu Zhongbang Pharmaceutical Company Information
      • 13.1.2 Jiangsu Zhongbang Pharmaceutical Telmisartan API Product Portfolios and Specifications
      • 13.1.3 Jiangsu Zhongbang Pharmaceutical Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 Jiangsu Zhongbang Pharmaceutical Main Business Overview
      • 13.1.5 Jiangsu Zhongbang Pharmaceutical Latest Developments
    • 13.2 Jiangxi Synergy Pharmaceutical
      • 13.2.1 Jiangxi Synergy Pharmaceutical Company Information
      • 13.2.2 Jiangxi Synergy Pharmaceutical Telmisartan API Product Portfolios and Specifications
      • 13.2.3 Jiangxi Synergy Pharmaceutical Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Jiangxi Synergy Pharmaceutical Main Business Overview
      • 13.2.5 Jiangxi Synergy Pharmaceutical Latest Developments
    • 13.3 Zhejiang Huahai Pharmaceutical
      • 13.3.1 Zhejiang Huahai Pharmaceutical Company Information
      • 13.3.2 Zhejiang Huahai Pharmaceutical Telmisartan API Product Portfolios and Specifications
      • 13.3.3 Zhejiang Huahai Pharmaceutical Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Zhejiang Huahai Pharmaceutical Main Business Overview
      • 13.3.5 Zhejiang Huahai Pharmaceutical Latest Developments
    • 13.4 Zhejiang Tianyu Pharmaceutical
      • 13.4.1 Zhejiang Tianyu Pharmaceutical Company Information
      • 13.4.2 Zhejiang Tianyu Pharmaceutical Telmisartan API Product Portfolios and Specifications
      • 13.4.3 Zhejiang Tianyu Pharmaceutical Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Zhejiang Tianyu Pharmaceutical Main Business Overview
      • 13.4.5 Zhejiang Tianyu Pharmaceutical Latest Developments
    • 13.5 Zhuhai Rundu Pharmaceutical
      • 13.5.1 Zhuhai Rundu Pharmaceutical Company Information
      • 13.5.2 Zhuhai Rundu Pharmaceutical Telmisartan API Product Portfolios and Specifications
      • 13.5.3 Zhuhai Rundu Pharmaceutical Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Zhuhai Rundu Pharmaceutical Main Business Overview
      • 13.5.5 Zhuhai Rundu Pharmaceutical Latest Developments
    • 13.6 Gonane Pharma
      • 13.6.1 Gonane Pharma Company Information
      • 13.6.2 Gonane Pharma Telmisartan API Product Portfolios and Specifications
      • 13.6.3 Gonane Pharma Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 Gonane Pharma Main Business Overview
      • 13.6.5 Gonane Pharma Latest Developments
    • 13.7 Dr. Reddy's Laboratories
      • 13.7.1 Dr. Reddy's Laboratories Company Information
      • 13.7.2 Dr. Reddy's Laboratories Telmisartan API Product Portfolios and Specifications
      • 13.7.3 Dr. Reddy's Laboratories Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Dr. Reddy's Laboratories Main Business Overview
      • 13.7.5 Dr. Reddy's Laboratories Latest Developments
    • 13.8 Octavius Pharma Pvt. Ltd
      • 13.8.1 Octavius Pharma Pvt. Ltd Company Information
      • 13.8.2 Octavius Pharma Pvt. Ltd Telmisartan API Product Portfolios and Specifications
      • 13.8.3 Octavius Pharma Pvt. Ltd Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Octavius Pharma Pvt. Ltd Main Business Overview
      • 13.8.5 Octavius Pharma Pvt. Ltd Latest Developments
    • 13.9 Kekule Pharma
      • 13.9.1 Kekule Pharma Company Information
      • 13.9.2 Kekule Pharma Telmisartan API Product Portfolios and Specifications
      • 13.9.3 Kekule Pharma Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 Kekule Pharma Main Business Overview
      • 13.9.5 Kekule Pharma Latest Developments
    • 13.10 Zeon Health Industries
      • 13.10.1 Zeon Health Industries Company Information
      • 13.10.2 Zeon Health Industries Telmisartan API Product Portfolios and Specifications
      • 13.10.3 Zeon Health Industries Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 Zeon Health Industries Main Business Overview
      • 13.10.5 Zeon Health Industries Latest Developments
    • 13.11 Teva API
      • 13.11.1 Teva API Company Information
      • 13.11.2 Teva API Telmisartan API Product Portfolios and Specifications
      • 13.11.3 Teva API Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.11.4 Teva API Main Business Overview
      • 13.11.5 Teva API Latest Developments
    • 13.12 AGC Chemicals Europe
      • 13.12.1 AGC Chemicals Europe Company Information
      • 13.12.2 AGC Chemicals Europe Telmisartan API Product Portfolios and Specifications
      • 13.12.3 AGC Chemicals Europe Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.12.4 AGC Chemicals Europe Main Business Overview
      • 13.12.5 AGC Chemicals Europe Latest Developments
    • 13.13 Actavis Inc.
      • 13.13.1 Actavis Inc. Company Information
      • 13.13.2 Actavis Inc. Telmisartan API Product Portfolios and Specifications
      • 13.13.3 Actavis Inc. Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.13.4 Actavis Inc. Main Business Overview
      • 13.13.5 Actavis Inc. Latest Developments
    • 13.14 Tokuyama Corporation
      • 13.14.1 Tokuyama Corporation Company Information
      • 13.14.2 Tokuyama Corporation Telmisartan API Product Portfolios and Specifications
      • 13.14.3 Tokuyama Corporation Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.14.4 Tokuyama Corporation Main Business Overview
      • 13.14.5 Tokuyama Corporation Latest Developments
    • 13.15 Hoventa Pharma
      • 13.15.1 Hoventa Pharma Company Information
      • 13.15.2 Hoventa Pharma Telmisartan API Product Portfolios and Specifications
      • 13.15.3 Hoventa Pharma Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.15.4 Hoventa Pharma Main Business Overview
      • 13.15.5 Hoventa Pharma Latest Developments
    • 13.16 Saintsun Pharma
      • 13.16.1 Saintsun Pharma Company Information
      • 13.16.2 Saintsun Pharma Telmisartan API Product Portfolios and Specifications
      • 13.16.3 Saintsun Pharma Telmisartan API Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.16.4 Saintsun Pharma Main Business Overview
      • 13.16.5 Saintsun Pharma Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.